Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma

Immune checkpoint inhibitors (CPIs) have expanded treatment options for patients with solid tumors. Systemic corticosteroids (CSs) have an indispensable role in cancer care, but CS-related immunosuppression may counteract the CPI-driven antitumor immune response. This retrospective study investigate...

Descripción completa

Detalles Bibliográficos
Autores principales: Drakaki, Alexandra, Dhillon, Preet K, Wakelee, Heather, Chui, Stephen Y, Shim, Jinjoo, Kent, Matthew, Degaonkar, Viraj, Hoang, Tien, McNally, Virginia, Luhn, Patricia, Gutzmer, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553559/
https://www.ncbi.nlm.nih.gov/pubmed/33101774
http://dx.doi.org/10.1080/2162402X.2020.1824645

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553559/
https://www.ncbi.nlm.nih.gov/pubmed/33101774
http://dx.doi.org/10.1080/2162402X.2020.1824645

Ejemplares similares